Chronic Inflammatory Demyelinating Polyneuropathy Market is expected to portray promising scenarios, as it is estimated to reach $6577.10 million in 2030 which was initially valued at around $2723.44 million in 2021, thereby registering a CAGR of nearly 7.50% from 2022 to 2030.
During the COVID-19 epidemic, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market has played a critical role.
Харесвам
Коментирай
Сподели
